Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Sequencing in DTC: Lenvatinib and Sorafenib

April 1st 2016

TKI Dose Adjustment in Advanced DTC

April 1st 2016

Safety and Efficacy of Lenvatinib in Advanced DTC

April 1st 2016

Efficacy and Toxicity of Sorafenib in Advanced DTC

April 1st 2016

TKI Therapy for Advanced Thyroid Cancer

April 1st 2016

Systemic Therapy for RAI-Refractory DTC

April 1st 2016

RAI-Refractory Defined

April 1st 2016

Multidisciplinary Care: High-Risk DTC

April 1st 2016

Multidisciplinary Care of Low/Intermediate Risk DTC

April 1st 2016

Moving Toward Personalized Medicine in Advanced DTC

April 1st 2016

Molecular Testing in Thyroid Cancer

April 1st 2016

Initial Workup for Differentiated Thyroid Cancer

April 1st 2016

Erlotinib Bests Gefitinib in Phase III NSCLC Study

March 29th 2016

Treatment with gefitinib failed to show noninferiority compared with erlotinib for patients with pretreated non–small cell lung cancer.

Does Physician-Physician Communication Matter?

March 28th 2016

Faisal Musa, MD, reviews the case of a patient with large granulocytic leukemia and discusses why collaborating with the patient’s pathologist was so important to her diagnosis.

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

BRCA Mutations Linked to Longer Survival in Ovarian Cancer

March 19th 2016

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.

Combining and Sequencing Immunotherapies in NSCLC

March 18th 2016

Emerging Checkpoint Inhibitors for Lung Cancer

March 18th 2016

Immune-Related Response Criteria in NSCLC

March 18th 2016

NEXT PAGE
PREVIOUS PAGE